Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celgene’s Positive Phase III Data For Otezla In Scalp Psoriasis Could Yield Broader Label

Oct 09 2018

• By Joseph Haas

Psoriatic Skin_1200x675

Related Content

Celgene’s Otezla Grabs New Psoriatic Arthritis Patients As Launch Accelerates

Oct 23 2014

Celgene's Terrie Curran On Building, Broadening The I&I Franchise

Apr 04 2018

Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications

Jul 27 2018

More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS

Feb 28 2018

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount

Feb 22 2018

Related Companies

Bristol Myers Squibb Company

Novartis AG

Eli Lilly and Company

Johnson & Johnson

Sun Pharmaceutical Industries Ltd.

Additional Topics

Research & Development Clinical Trials Business Strategies Commercial BioPharmaceutical Inflammation

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window